OR WAIT null SECS
mRNA therapeutics are being researched to support the fight against rare diseases, infectious viruses, and cancers.
Arranta Bio signed a contract with the Massachusetts Institute of Technology (MIT) on April 28, 2023 to develop a continuous manufacturing technology for messenger RNA (mRNA) therapeutics. The contract is part of FDA’s initiative to have a fully integrated, continuous manufacturing production line for mRNA vaccines.
A three-year project, the plan is set to start the deployment of mRNA vaccines for rapid response against future pandemics and novel mRNA therapeutics to patients around the world. Additionally, mRNA therapeutics are being researched to support the fight against rare diseases, infectious viruses, and cancers.
Current challenges are planned to be addressed in the project for the continuous manufacturing of mRNA therapeutics. Under the terms of the agreement, FDA will directly support and inform the advances to enable Arranta Bio and MIT to push the boundaries of current manufacturing and testing processes, according to the press release.
“We are proud to be working with MIT on this ground-breaking FDA initiative to be forward thinkers and push the boundaries of biologics manufacturing. Our work can enable new vaccines and therapies to be deployed quickly and be economically viable for patients in need,” Marc Funk, CEO of Recipharm, said in a press release. “This project is yet another step towards our vision to be the CDMO of choice, for the benefit of patients.”